FILL FINISH MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

A growing preference among patients and care providers for drug delivery systems like pre-filled syringes and autoinjectors has biomedicine companies aggressively pursuing novel formulation strategies. Self-administration options improve compliance for chronic disease therapy and also enable subcutaneous delivery of biologics that were previously only available via intravenous methods. The development of highly concentrated biologic dosage forms has enabled devices like pre-filled syringes and autoinjectors that lower injection volumes and frequencies. However, working with such formulation poses several manufacturing complexities including ensuring drug substance stability in a small deliverable volume. Biologics fill finish providers are making extensive capital investments in automation technologies, isolator systems, and lyophilization capabilities to address these complexities. Leading contract manufacturing organizations are also developing specialized expertise in assembly, packaging and labeling of combination products. This is helping biopharmaceutical innovators to increasingly adopt advanced drug delivery systems and expand patient access to self-administered biologic therapies.

• Asymchem Inc.
• Syntegon Technology GmbH
• I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A
• West Pharmaceutical Services, Inc.
• Gerresheimer AG 
• AptarGroup, Inc.
• Dätwyler Holding Inc.
• Stevanato Group
• OPTIMA
• SGD Pharma 
• Nipro Corporation
• Bausch Advanced Technology Group
• Berry Global Inc.